NR (Nicotinamide Riboside)
NR is a vitamin B3 form and NAD+ precursor that reliably elevates whole blood NAD+ by 40-90% in human trials at 250-1000 mg daily. It activates sirtuins and is well studied for metabolic and mitochondrial health.
Community Rating
No ratings yet
Compound Profile
NR (Nicotinamide Riboside)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. NR (Nicotinamide Riboside) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Consistently raises whole blood NAD+ by 40-90% at 250-1000 mg/day in multiple human RCTs
- Activates SIRT1, SIRT3, and SIRT5 deacylases, improving mitochondrial biogenesis markers
- Reduces liver fat and improves hepatic NAD+ in non-alcoholic fatty liver disease models
- NR (Nicotinamide Riboside) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Consistently raises whole blood NAD+ by 40-90% at 250-1000 mg/day in multiple human RCTs
- Activates SIRT1, SIRT3, and SIRT5 deacylases, improving mitochondrial biogenesis markers
- Reduces liver fat and improves hepatic NAD+ in non-alcoholic fatty liver disease models
- Improves physical performance and muscle mitochondrial function in aging populations
In Plain English
Simple summaryNR (nicotinamide riboside) is a form of vitamin B3 and one of the most studied NAD+ precursors. It's naturally present in small amounts in milk and converted to NMN and then NAD+ through a two-step enzymatic pathway. Elysium Health and ChromaDex (Tru Niagen) commercialized it heavily after a landmark 2013 Cell Metabolism paper showed NR supplementation restored NAD+ and improved mitochondrial function in aged mice. Human trials have since confirmed that NR reliably raises blood NAD+ in healthy adults at doses of 500-2000 mg/day. The debate is whether any of that translates to meaningful human health outcomes -- and in that department, the evidence is considerably thinner than the marketing suggests.
- Consistently raises whole blood NAD+ by 40-90% at 250-1000 mg/day in multiple human RCTs
- Activates SIRT1, SIRT3, and SIRT5 deacylases, improving mitochondrial biogenesis markers
- Reduces liver fat and improves hepatic NAD+ in non-alcoholic fatty liver disease models
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is NR (Nicotinamide Riboside)?
Tap any underlined term for an instant definition.
NR (Nicotinamide Riboside) is a form of vitamin B3 (niacin) and an established oral NAD+ precursor. It is present in trace amounts in milk and certain foods. NR enters the NAD+ biosynthesis pathway via nicotinamide riboside kinases (NRK1 and NRK2), which phosphorylate NR to NMN, which is then converted to NAD+ by NMNAT enzymes.
NR was identified as a bioavailable NAD+ precursor in a landmark 2004 study (Bieganowski and Brenner, Cell), and its ability to raise blood NAD+ in humans was first confirmed in 2016 (Trammell et al., Nature Communications). Since then, it has become one of the most studied longevity compounds in human clinical trials.
The commercial NR product Tru Niagen (ChromaDex) has been through multiple peer-reviewed RCTs including CAMINO (300 vs 1000 mg/day), showing dose-dependent NAD+ elevation in whole blood, with the 1000 mg dose achieving approximately 90% increase from baseline.
Like NMN, the therapeutic rationale for NR supplementation rests on the well-documented decline in tissue NAD+ with aging, the critical roles of NAD+ in sirtuin activation (particularly SIRT1, SIRT3, SIRT5), PARP-mediated DNA repair, and mitochondrial energy metabolism (Complex I requires NAD+).
NR vs NMN differences include: NR requires two enzymatic steps to become NAD+ (vs NMN's one step); NR may have better tissue distribution in certain cell types (particularly liver and neurons via NRK1); NMN may be more efficient in skeletal muscle. Both reliably elevate circulating NAD+ metabolites.
Research applications include neurodegenerative disease (mouse models of ALS, Alzheimer's, and Parkinson's), cardiovascular aging, metabolic syndrome, exercise physiology, and healthy aging protocols.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on NR (Nicotinamide Riboside). See all Immune System peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
NR research protocols use 250-1000 mg daily. Most human clinical trials have used 300 mg or 1000 mg/day as a single dose or split into two doses.
Standard research dose: 300-500 mg daily Higher studied doses: 1000 mg/day (well tolerated up to 8 weeks in RCTs) Timing: Morning with food Duration: 4-12 weeks for most NAD+ augmentation studies
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
NR is typically administered orally as a capsule. Unlike NMN, there is less rationale for sublingual delivery as NR is well absorbed enterally and converted to NMN in tissues via NRK1/2 kinases.
What the research doesn't show
NR has been studied more rigorously than most supplements, which is admirable. But the human trials haven't found the dramatic healthspan improvements that the mouse data promised. A 2023 NEJM paper found NR did not improve cardiovascular outcomes in heart failure patients. Raising NAD+ is real; the functional benefits in healthy humans are not clearly established. The supplement industry has gotten ahead of the science here.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain NR (Nicotinamide Riboside), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
NR (Nicotinamide Riboside) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: consistently raises whole blood nad+ by 40-90% at 250-1000 mg/day in multiple human rcts.
The most commonly reported side effect in research subjects is generally well tolerated; no clinically significant adverse effects at 1000 mg/day in 8-week trials. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
Research Articles
- NMN vs NR: Comparing NAD+ Precursor Bioavailability and Research Evidence8 min read
- NAD+ vs Epithalon: Two Different Approaches to Cellular Aging Research7 min read
How It Compares
NMN is one metabolic step further toward NAD+ in the biosynthesis pathway. In practice, both raise blood NAD+ to similar degrees at comparable doses. Niacin is the cheapest NAD+ precursor but causes uncomfortable skin flushing through a prostaglandin-mediated mechanism; NR and NMN don't flush. Nicotinamide (niacinamide) is another B3 form but may actually inhibit sirtuins at high doses by a feedback mechanism.
Compare NR (Nicotinamide Riboside) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.